PMEL and neoplasm: Some tumor sections were immunostained with ready-to-use primary antibodies against broad-spectrum cytokeratin (CK), vimentin, calretinin, Wilms tumor gene-1 (WT-1), D2–40, Paird box 8, synaptophysin, chromogranin-A, inhibin-α, S-100, Melan-A, HMB45, CD34, and Ki-67 (Maixin, Fuzhou, China).